KR20200117524A - PTPσ gene for treating or preventing anxiety disorders and screening methods using the same - Google Patents

Abstract

The present application relates to a PTPσ gene for preventing or treating anxiety disorders, and uses thereof. More specifically, the present invention provides a pharmaceutical composition for preventing or treating anxiety disorders comprising an inhibitor of the expression or activity of PTPσ protein as an active component, and a method for screening an anxiety disorder therapeutic agent comprising a step of measuring the expression or activity level of the PTPσ protein.

Description

PTPσ gene for preventing or treating anxiety disorders and screening methods using the same {PTPσ gene for treating or preventing anxiety disorders and screening methods using the same}

It relates to the PTPσ　 gene for preventing or treating anxiety disorders and a screening method using the same.

Anxiety disorder is a mental disorder that disrupts daily life due to pathological anxiety about the future and excessive fear of the present situation. Specifically, a disease in which chronic anxiety or anxiety occurs, and thus a variety of physical or mental symptoms, is referred to as an anxiety disorder. Feelings of anxiety appear excessively and widely, and are accompanied by various physical symptoms.There are cases where anxiety, anxiety, and anxiety are specific, but there are also unfounded anxieties such as vague feelings that something terrible will happen. Because of anxiety, he is always in a tense state, and his autonomic nerves are sharp, which is a lot of obstacles to daily life. It is said that approximately 25% of the general population experiences anxiety disorders, and in particular, it is known that about two times more women than men.

However, it is currently not clear how anxiety disorder is triggered. In particular, it is common to see anxiety disorder as a disease occurring in the brain, and in particular, there is a lack of understanding of the neural circuits that cause anxiety disorders (Korean Patent Laid-Open Patent 10-2014-0122527). To date, various animal models related to anxiety disorders have been produced and reported to analyze the cause of anxiety disorders and overcome the disorders, but the exact mechanism of action and modulators of the relevant circuits are not known yet. Because of this It is a situation that is having great difficulty in developing treatments and preventing anxiety disorders such as panic disorder or obsessive compulsive disorder, which are a major social problem.

One aspect is to provide a pharmaceutical composition for the prevention or treatment of anxiety disorders, comprising an inhibitor of the expression or activity of protein PTPσ (Protein tyrosine phosphatase receptor type sigma) as an active ingredient.

Another aspect includes measuring the expression or activity level of the PTPσ protein in cells contacted with a candidate substance for the treatment of anxiety disorder; And comparing the measured expression or activity level of the PTPσ protein with the expression or activity level of a control cell not contacted with a candidate substance, to provide a method for screening an anxiety disorder therapeutic agent.

One aspect provides a pharmaceutical composition for preventing or treating anxiety disorders, comprising an inhibitor of the expression or activity of protein PTPσ (Protein tyrosine phosphatase receptor type sigma) as an active ingredient.

As used herein, the term "prevention" refers to any action that suppresses or delays the onset of anxiety disorder by administration of the composition.

As used herein, the term “treatment” refers to an individual suffering from or at risk of developing a disease, improving the condition (eg, one or more symptoms) of the individual, delaying the progression of the disease, and developing symptoms. It refers to any form of treatment that provides an effect, including delaying or slowing the progression of symptoms. Thus, the "treatment" and "prevention" are not intended to mean cure or complete elimination of symptoms.

The "individual" refers to a subject in need of treatment of a disease, and more specifically, refers to a mammal such as a human or non-human primate, mouse, dog, cat, horse, and cow.

The disease to be prevented or treated by the pharmaceutical composition, "anxiety disorder" is a diagnostic and statistical manual for mental disorders published in 2000 (DSM-IV-TR) and 2013 (DSM-5), respectively , 4th or 5th edition (the Diagnostic and Statistical Manual of Mental Disorders, Fourth or Fifth Editions) is understood to encompass those conditions defined as anxiety disorders. The anxiety disorder may be any one selected from the group consisting of separation or isolation anxiety, paranoia, panphobia, pan-obsessive compulsive disorder, neurotic anxiety, and panic disorder.

According to an embodiment, in experimental mice that specifically knock-down or knock-out the PTPσ gene in the prefrontal lobe region and the hippocampal gyrus region, anxiety behavior There was a decreased phenotype, and in particular, this effect was behaviorally specific in relation to anxiety disorders without affecting other phenotypes such as memory. Thus, inhibition of the expression or activity of the PTPσ gene can be used to prevent or treat anxiety disorder diseases.

As used herein, the term "PTPσ (Protein tyrosine phosphatase receptor type sigma) protein" is a protein that plays an important role in neurodevelopment and has a weight of about 200kDa. The PTPσ protein is known to contain 1948 amino acids, of which 29 are in the signal sequence and 1253 are in the extracellular domain. The extracellular domain binds to various proteoglycans, which regulate the activity of two intracellular PTP domains, D1 and D2. On the other hand, the sequence of the PTPσ protein or a gene encoding it can be obtained from a known database such as GenBank of the National Institutes of Health.

In the present specification, the term "protein" may be used with the same meaning as "polypeptide" or "polypeptide", and refers to a polymer of amino acid residues. Proteins apply to amino acid polymers, in which one or more amino acid residues are artificial chemical mimics of the corresponding naturally occurring amino acids, as well as naturally occurring amino acid polymers, those containing modified residues, and non-naturally occurring amino acid polymers.

In the present specification, the term "knockout" refers to inducing complete inactivation of a normal gene by introducing a DNA in which a gene is defective from the outside, and the term "knockdown" refers to, for example, RNAi, etc. It means reducing the amount of gene expression by degrading the expressed mRNA.

The inhibitor of expression or activity of the PTPσ protein refers to a substance that inhibits or interferes with the function of the PTPσ protein. Such inhibition or interference may be achieved by interfering with the transcription of the PTPσ gene or by inhibiting the translation of the mRNA of the PTPσ gene. Alternatively, the activity of the PTPσ protein can be reduced or inactivated by specifically binding to the active site of the PTPσ protein or causing a protein structure modification.

The expression inhibitor of the PTPσ protein may be an antisense nucleotide complementarily binding to PTPσ mRNA, a small interfering RNA (siRNA), or a short hairpin RNA (shRNA). The inhibitor of the activity may refer to a substance that makes the same type of activity lower than that of a parental cell that is not genetically engineered (eg, wild type) or has an intrinsic activity. The inhibitor of the activity of the PTPσ protein may be a compound, peptide, peptide mimetics, aptamer, antibody, or natural product that specifically binds to the PTPσ protein.

These nucleotides are the building blocks of oligonucleotides and polynucleotides, and include both naturally occurring and non-naturally occurring nucleotides for the purposes of the present invention. Naturally, nucleotides, such as DNA and RNA nucleotides, contain ribose sugar moieties, nucleobase moieties and one or more phosphate groups (absent in nucleosides). Nucleosides and nucleotides may also be referred to interchangeably with “units” or “monomers”.

The meaning of the "complementary binding" relates to the Watson-Crick base pair of nucleosides/nucleotides. Watson-Crick base pairs are guanine (G)-cytosine (C) and adenine (A)-thymine (T)/uracil (U). Oligonucleotides may contain nucleosides with modified nucleobases. For example, 5-methyl cytosine is often used in place of cytosine. The term “complementarily bonded” may include Watson-Crick base-bonding between a non-modified nucleobase and a modified nucleobase (see, eg, Hirao et al (2012) Accounts of Chemical Research. vol 45 page 2055 and Bergstrom (2009) Current Protocols in Nucleic Acid Chemistry Suppl. 37 1.4.1).

The antisense nucleotide is defined as an oligonucleotide capable of regulating the expression of a target gene by hybridizing to a target nucleic acid, particularly a contiguous sequence on the target nucleic acid. Antisense oligonucleotides are not essentially double-stranded, and therefore not siRNA or shRNA.

The term "small interfering RNA" refers to an RNA capable of inducing RNA interference (RNAi) that inhibits the activity of a gene. The small interfering RNA may be miRNA or siRNA capable of inhibiting the expression of the PTPσ gene, and the small interfering RNA may be in any form as long as it suppresses the expression or activity of the PTPσ gene. For example, siRNA obtained by chemical synthesis or biochemical synthesis or in vivo synthesis, or double-stranded RNA of 10 bases or more in which a double-stranded RNA of about 40 bases or more is degraded in the body can be used.

The "aptamer" refers to a nucleic acid molecule having binding activity to a predetermined target molecule. The aptamer may be RNA, DNA, a modified nucleic acid, or a mixture thereof, and may be in a linear or cyclic form.In general, the shorter the nucleotide sequence constituting the aptamer, the more chemical synthesis and mass production is. It is known that it is easier, has excellent cost advantages, is easy to chemically formulate, has excellent in vivo stability, and has low toxicity.

The "antibody" refers to a proteinaceous molecule capable of specifically binding to an antigenic site of a protein or peptide molecule, and such an antibody is cloned into an expression vector according to a conventional method and It is possible to obtain a protein encoded by the obtained protein by a conventional method. The form of the antibody is not particularly limited, and if a polyclonal antibody, a monoclonal antibody, or any one having antigen binding properties, a part thereof is also included in the antibody of the present invention, and all immunoglobulin antibodies may be included, as well as humanized antibodies, etc. It may also contain a special antibody of. In addition, the antibody includes a complete form having two full-length light chains and two full-length heavy chains as well as functional fragments of antibody molecules. The functional fragment of an antibody molecule refers to a fragment having at least an antigen-binding function, and may be Fab, F(ab'), F(ab')2, Fv, and the like.

In one embodiment, the composition may be one that specifically acts on excitatory synapses. The excitatory synapse refers to a synapse in which an action potential in a presynaptic neuron increases the probability that an action potential occurs in a post-synaptic cell. Neurons form a network through which nerve impulses move, each of which forms numerous connections with other cells. These electrical signals may be excitatory or inhibitory, but if the total excitatory effect is greater than the total inhibitory effect, nerve cells may be stimulated. That is, by providing a new action potential in the axon hillock of the nerve cell, information can be transmitted to other cells. This phenomenon is called excitatory postsynaptic potential (EPSP). This can occur through direct contact between cells (eg, via gap junction), as in electrical synapses. However, most commonly, as in chemical synapses, it occurs through vesicular release of neurotransmitters from the presynaptic axon end to the synaptic cleft (cleft). Excitatory neurotransmitters can bind to specific transmembrane receptor proteins, which migrate through diffusion to the dendritic spine of neurons after synapses and trigger depolarization of the cells.

In one embodiment, the composition may be one that acts on the prefrontal lobe and the hippocampal gyrus region. The prefrontal lobe is defined as the cerebral cortex located in the forehead of the head, and is a region for predicting or judging behavior. It stores important and non-critical memories and maintains a person's awakening state, pleasure and pain, worry and anger, It is known to be in charge of emotional reactions such as fear and aggression, but there is no known fact about the specific control of anxiety disorders.

The pharmaceutical composition may contain one or more pharmaceutically acceptable carriers in addition to the active ingredients described above. Pharmaceutically acceptable carriers can be used by mixing saline, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol, liposome, and one or more of these components, and if necessary, antioxidants , Buffers, bacteriostatic agents, and other conventional additives may be added. In addition, diluents, dispersants, surfactants, binders, and lubricants can be additionally added to form injectable formulations such as aqueous solutions, suspensions, emulsions, etc., pills, capsules, granules, or tablets, and can act specifically on target organs. Thus, a target organ-specific antibody or other ligand may be used in combination with the carrier.

The pharmaceutical composition may be administered parenterally, subcutaneously, intravenously, intramuscularly, intraperitoneally, transdermally or orally. Alternatively, the medicament can be administered orally or directly to the target organ. The dosage may be determined in light of the patient's age, sex, health condition and weight, type of concurrent treatment, administration time, administration method, excretion rate, disease severity, frequency of treatment, and properties of desired effects. In addition, it can be administered systemically or locally in consideration of conditions such as the disease to be treated, the need for site-specific treatment, and the amount of drug to be administered.

The pharmaceutical composition may have any pharmaceutical formulation. For example, a form suitable for oral administration as a tablet, capsule, pill, powder, sustained-release formulation, solution, or suspension, a form suitable for parenteral injection as a sterile solution, suspension or emulsion, or for topical administration as an ointment or cream. It may be in a suitable form, or a form suitable for rectal administration as a suppository. The composition may be a tablet, a pill, an injection, or a combination thereof. The pharmaceutical composition may be in a unit dosage form suitable for single administration of the correct dosage.

In providing the pharmaceutical composition or performing the treatment of a disease using the pharmaceutical composition, the pharmaceutical composition may be used alone or in combination, or in combination with other therapeutic agents or diagnostic agents. In one embodiment, the pharmaceutical composition may be administered concurrently with other agents typically prescribed for the intended disease according to generally accepted medical practice. In addition, the pharmaceutical composition can be used in vivo in a mammal, for example, a human in general.

Another aspect is a method of treating anxiety disorder, comprising administering to a subject an inhibitor of the expression or activity of the PTPσ protein, or a pharmaceutical composition comprising the same; And it provides a pharmaceutical use of the expression or activity inhibitor of the PTPσ protein or a pharmaceutical composition comprising the same for the treatment of anxiety disorder or to prepare a therapeutic agent for anxiety disorder.

Another aspect is the step of measuring the expression or activity level of PTPσ (Protein tyrosine phosphatase receptor type sigma) protein in cells contacted with a candidate substance for the treatment of anxiety disorder; And comparing the measured expression or activity level of the PTPσ protein with the expression or activity level of a control cell not contacted with a candidate substance.

Among the terms or elements mentioned in the description of the method for screening, the same as those already mentioned are as described above.

As used herein, the term "candidate" refers to a substance that is expected to inhibit the expression or activity of the PTPσ protein as described above, and is a low molecular weight compound, a high molecular weight compound, a mixture of compounds (eg, natural extracts or cells or Tissue culture), or biopharmaceuticals (eg, proteins, antibodies, peptides, DNA, RNA, antisense oligonucleotides, RNAi, aptamers, RNAzyme and DNAzyme), or sugars and lipids.

In one embodiment, the cell may be a cell containing a PTPσ protein or a precursor thereof, for example, the cell may be a cell derived from the prefrontal lobe and hippocampal gyrus region.

In the above method, "Contacting" is in the general sense, and combining two or more agents (eg, two polypeptides), or combining agents and cells (eg, proteins and cells), etc. May refer to. Contact can also occur in vitro. For example, two or more agents may be combined in a test tube or other container, or a test agent and cells or cell lysates and a test agent may be combined. In addition, contact may occur in cells or in situ. For example, two polypeptides can be contacted in a cell or cell lysate by coexpressing a recombinant polynucleotide encoding two polypeptides in a cell. In addition, a protein chip or protein array in which the protein to be tested is arranged on the surface of the stationary bed can be used.

In the above method, when the expression level of the PTPσ protein measured in cells contacted with the candidate substance is decreased compared to the non-contact control, determining or selecting as an anxiety disorder treatment agent may be further included. The change in the expression level is similar to that of the untreated control or negative control, or 1%, 2%, 3%, 4%, 5%, 10%, 20%, 30%, 40% of the expression level of the PTPσ protein. Including reductions of 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900% and 1000% or more can do.

In one embodiment, the anxiety disorder therapeutic agent may specifically regulate the activity of excitatory synapses.

In another embodiment, the anxiety disorder therapeutic agent may be screened by a method that specifically modulates the activity of an excitatory synapse.

The step of measuring the expression or activity level of the PTPσ protein may be performed through various methods known in the art, for example, RT-PCR, competitive RT-PCR, and real-time RT-PCR. (Real-time RT-PCR), RNase protection assay (RPA), Northern blotting, nucleic acid microarray including DNA, Western blotting, ELISA (enzyme linked immunosorbent assay), radioimmunoassay (Radioimmunoassay, RIA), radioimmunodiffusion, Ouchterlony immune diffusion method, rocket immunoelectrophoresis, tissue immunostaining, immunoprecipitation assay (Immunoprecipitation Assay), complement fixation assay (Complement Fixation Assay) ), FACS, mass spectrometry, magnetic bead-antibody immunoprecipitation, protein chip, enzyme activity evaluation, etc. can be used.

According to one aspect, as a result of conducting behavioral experiments by making knock-out mice specific to the prefrontal lobe and hippocampal lobe regions of the PTPσ protein, anxiety behaviors were significantly reduced compared to normal mice. Confirmed. Therefore, the PTPσ gene may be usefully utilized for the prevention or treatment of anxiety disorders, and may also be used in a method for screening an anxiety disorder therapeutic agent.

Figure 1 is a comparison between the experimental mice having the PTPσ f / f gene and the mice having the PTPσ f / f; Wfs1-Cre gene. The left is a photograph showing the results of an elevated cross maze experiment, and the right is a graph showing the time and number of entries two rats stay in the closed arm (CA) and open arm (OA), respectively.
Figure 2 is a comparison of the experimental mice having the PTPσ f / f gene and the mice having the PTPσ f / f; EMX1-Cre gene. The left is a photograph showing the results of an elevated cross maze experiment, and the right is a graph showing the time and number of entries two rats stay in the closed arm (CA) and the open arm (OA), respectively.
Figure 3 is a comparison between the experimental mice having the PTPσ f / f gene and the mice having the PTPσ f / f; Wfs1-Cre gene. The left is a picture showing the results of the Y-maze experiment, and the right is a graph showing the results.
Figure 4 is a comparison between the experimental mice having the PTPσ f / f gene and the mice having the PTPσ f / f; Wfs1-Cre gene. The left is a photograph showing the results of the novel object recognition test, and the right is a graph showing the results.

Hereinafter, the present invention will be described in more detail through examples. However, these examples are for illustrative purposes only, and the scope of the present invention is not limited to these examples.

Example 1. PTPσ gene knock-out mouse production and line construction

In this example, a corresponding knock-out mouse was prepared using a Cre/loxP site-specific recombination method to analyze the behavioral changes caused by knock-out of the PTPσ gene. The process of making a knockout mouse is as follows. PTPσ f/f mice with loxP-specific sequences on both sides of the fourth exon of the PTPσ gene were crossed with Wfs1-Cre driver mice that specifically express Cre recombinase in the prefrontal and hippocampal lobes. In PTPσ f/f;Wfs1-Cre mice born from mated mothers, the nucleotide sequence between the two loxPs of the PTPσ gene was deleted according to the loxP sequence recognition and recombination of the Cre enzyme, and as a result, the PTPσ gene due to exon 4 deficiency. A knockout was induced. In the following examples, the experimental mice prepared as described above were used as knock-out mice of the PTPσ gene.

Example 2. Confirmation of behavioral changes related to anxiety disorder

In this example, in order to confirm the behavioral changes related to anxiety disorders due to knock-out of the PTPσ gene, an experiment using an elevated-plus maze device was performed.

The preparation process for the experiment is as follows. A cross-shaped maze was installed horizontally with the ground at a height of 75cm from the ground so that the mice could not come down arbitrarily. Each arm of the cross is used as a passage through which the rat can move, and is designed to be 5 cm wide and 30 cm long. Among them, a wall with a height of 15 cm was installed on the pair of arms facing each other to form a closed arm (CA), and the other pair of arms facing each other was prepared as an open arm (OA). The device is made of plastic material, the cross-shaped bottom is white and the walls are designed to be opaque. The mice were reared in a place with a 12-hour light and dark cycle, repeating the process of turning on the light at 7 am and removing the light at 7 pm.

Then, the experiment was conducted in the following manner. This experiment was conducted between 12 pm and 4 pm. All mice were transferred to the laboratory 30 minutes before the start of the experiment in order to become accustomed to the laboratory environment. The laboratory is soundproofed and prepared with a red light on. At the beginning of the experiment, the mice were placed in the center of the cross maze with their heads toward the closed arms. The mice were allowed to freely move the expensive crucifix for 5 minutes. Each rat went through the experiment once, and after each test, all arms and the central part of the cross were washed with 70% ethanol to exclude the effect of olfactory sense.

This experiment was recorded using a video camera controlled by a remote device. AxioVision 3.0 imaging system (Carl Zeiss, Inc., Oberkochen., Germany) is the ratio of the total distance the mice traveled, the number of entries in each arm, the time spent in each arm, and the number of entries in the open arm to the closed arm. ) Was measured. Here, the "number of entry" was defined as the number of times the center of gravity of the rat entered each arm. These measurements became an indicator of the anxiety behavior of the mice, and as a result, it was evaluated that the longer the time the mice stayed in the closed arm, the more anxious the mice felt. In addition, if two rats with different characteristics showed different results in the above measurement, it was evaluated that there was a difference in anxiety behavior.

1 is a comparison between mice expressing only PTPσ f/f (PTPσ f/f) and mice expressing PTPσ f/f and Wfs1-Cre simultaneously (PTPσ f/f; Wfs1-Cre). PTPσ f/f is an experimental mouse in which loxP sequences were introduced into both sides of the PTPσ gene, and PTPσ f/f; Wfs1-Cre is an experimental mouse that specifically inserted the Cre gene in the prefrontal lobe and hippocampal gyrus region along with PTPσ f/f, and knocked out the PTPσ gene in this region. The left is a photograph showing the location of a mouse in a cross maze over time. On the other hand, the right side is a graph showing the time and the number of times the two mice stay in the closed and open arms, respectively.

Figure 2 is a comparison of the mice (PTPσ f/f; EMX1-Cre) expressing PTPσ f/f and PTPσ f/f and EMX1-Cre at the same time. PTPσ f/f; EMX1-Cre is an experimental mouse that specifically inserted a Cre gene in an excitatory synaptic site along with PTPσ f/f and knocked out the PTPσ gene in this site. The left is a photograph showing the location of the rats staying in the cross maze over time, and the right is a graph showing the time and the number of entry of the two rats in the closed and open arms, respectively.

As a result, in FIG. 1, it was found that a reduced phenotype of anxiety behavior was observed in mice that specifically knocked out the PTPσ gene in the prefrontal lobe region and the hippocampal gyrus region. In addition, in Fig. 2, it can be seen that a decreased phenotype of anxiety behavior was observed in mice that specifically knocked out the PTPσ gene at the excitatory synapse.

Example 3. Confirmation of specific effect on anxiety disorder

In this example, in order to confirm changes in memory due to knock-out of the PTPσ gene in the prefrontal and hippocampal gyrus regions, a maze Y test and a Novel object recognition test were performed.

For the Y-maze test, a Y-shaped white acrylic maze was used. Each Y-shaped arm is 40cm long, and the three arms are separated at an angle of 120° each. The mice were placed in the center of the maze and allowed to move freely for 8 minutes. The number of times was recorded whenever all four legs of the rat entered into the arm. The mice's movements were recorded with a top-view infrared camera and analyzed using EthoVision XT 10 software (Noldus). Rats generally tend to explore the maze's new arm rather than go to the arm it had previously entered. Therefore, it can be seen that the memory capacity decreased as the mice reentered the arm they had previously entered.

As a result, in FIG. 3, it was found that the experimental mice that specifically knocked out the PTPσ gene in the prefrontal and hippocampal gyrus regions had no significant difference in memory compared to the control mice.

The novel object recognition test used an open field chamber. The mice were placed in the chamber for 10 minutes to become accustomed to the chamber. During training, two identical objects were placed in the center of the chamber at regular intervals, and the mice were allowed to grope them for 10 minutes. After the training period, the mice were kept in cages for 6 hours. For the new object recognition test, one of the two objects was replaced with a new object and placed in the same location in the chamber. The mice were re-entered and allowed to grope freely for 10 minutes. The movements of the mice were recorded with an infrared camera, and the number and duration of contacts were analyzed using EthoVision XT 10 (Noldus). Rats have a habit of groping for new objects. Therefore, when one of the two objects is replaced and placed in the chamber in the rat, it can be determined that the memory of the rat has not decreased if the rat spends a long time in the new object.

As a result, in FIG. 4, it was found that the experimental mice that specifically knocked out the PTPσ gene in the prefrontal lobe and hippocampal gyrus regions had no significant difference in memory compared to the control mice. Therefore, from these experimental results, it was found that the effect of inhibition of the aforementioned PTPσ gene was specific to the anxiety behavior phenotype.

Claims (12)

PTPσ (Protein tyrosine phosphatase receptor type sigma) a pharmaceutical composition for the prevention or treatment of anxiety disorders comprising an inhibitor of protein expression or activity as an active ingredient. The method according to claim 1, wherein the PTPσ protein expression inhibitor is a binding antisense nucleotide that binds complementarily to PTPσ mRNA, small interfering RNA (siRNA), short hairpin RNA (shRNA), and combinations thereof. Which one is selected from the group consisting of, the pharmaceutical composition. The method according to claim 1, wherein the PTPσ protein activity inhibitor is any one selected from the group consisting of compounds, peptides, peptide mimetics, aptamers, antibodies, natural products, and combinations thereof that specifically bind to PTPσ protein, Pharmaceutical composition. The pharmaceutical composition of claim 1, wherein the composition specifically acts on excitatory synapses. The pharmaceutical composition of claim 1, wherein the composition acts on the anterior frontal lobe and the hippocampal gyrus region. The pharmaceutical composition of claim 1, wherein the anxiety disorder is selected from the group consisting of separation or isolation anxiety, paranoia, panphobia, panic obsessive compulsive disorder, neurotic anxiety, and panic disorder. Measuring the expression or activity level of PTPσ (Protein tyrosine phosphatase receptor type sigma) protein in cells contacted with a candidate substance for treatment of anxiety disorder; And
Comprising the step of comparing the measured expression or activity level of the PTPσ protein with the expression or activity level of a control cell not contacted with the candidate substance, a method for screening an anxiety disorder therapeutic agent. The method of claim 7, wherein the cells are cells derived from the prefrontal lobe and hippocampal lobe regions. The method of claim 7, wherein the anxiety disorder is selected from the group consisting of separation or isolation anxiety, paranoia, panphobia, panic compulsive disorder, neurotic anxiety, and panic disorder. The method of claim 7, wherein the step of measuring the expression or activity level of the PTPσ protein comprises RT-PCR, competitive RT-PCR, Real-time RT-PCR, and RNase protection assay ( RNase protection assay: RPA), Northern blotting, nucleic acid microarray including DNA, western blotting, ELISA (enzyme linked immunosorbent assay), radioimmunoassay (RIA), radioimmunodiffusion, Ouchterlony immune diffusion method, rocket immunoelectrophoresis, tissue immunostaining, Immunoprecipitation Assay, Complement Fixation Assay, FACS, mass spectrometry, magnet bead-antibody immune sedimentation Method, protein chip (protein chip), or a method for screening an anxiety disorder therapeutic agent that is performed by a combination thereof. The anxiety disorder therapeutic agent according to claim 7, further comprising the step of determining the candidate substance as an anxiety disorder therapeutic agent when the expression or activity level of the PTPσ protein of the cell contacted with the candidate substance is decreased compared to the control cell. How to screen. The method of claim 11, wherein the anxiety disorder therapeutic agent specifically modulates the activity of an excitatory synapse.

Images